We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

65 hedge funds and large institutions have $75.5M invested in Gyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,982% more call options, than puts

Call options by funds: $5.11M | Put options by funds: $84K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.79% less ownership

Funds ownership: 8.61% → 7.81% (-0.79%)

6% less funds holding

Funds holding: 69 → 65 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

14% less capital invested

Capital invested by funds: $87.7M → $75.5M (-$12.2M)

71% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 31

Holders
65
Holders Change
-4
Holders Change %
-5.8%
% of All Funds
1.14%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
9
Reduced
31
Closed
16
Calls
$5.11M
Puts
$84K
Net Calls
+$5.03M
Net Calls Change
+$3.22M

Top Buyers

1
O
OrbiMed
New York
+$2.6M
2
PVI
Pura Vida Investments
New York
+$1.63M
3
SM
Sabby Management
Florida
+$464K
4
Citadel Advisors
Citadel Advisors
Florida
+$287K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

1
SCM
Stonepine Capital Management
Oregon
-$1.94M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.79M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.68M
4
ACP
Acuta Capital Partners
California
-$1.4M
5
PHP
Parkman Healthcare Partners
Connecticut
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$11.1M +$2.6M +79,067 +28%
SCM
2
Stonepine Capital Management
Oregon
$10.8M -$1.94M -58,848 -14%
NCM
3
Nantahala Capital Management
Connecticut
$10M -$435K -13,220 -4%
2L
4
22NW LP
Washington
$5.87M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.85M +$4.61K +140 +0.1%
GTC
6
Ghost Tree Capital
New York
$4.11M – – –
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$3.29M -$545K -16,568 -13%
Millennium Management
8
Millennium Management
New York
$2.76M -$511K -15,536 -15%
SCM
9
Sio Capital Management
New York
$2.56M – – –
IC
10
Ikarian Capital
Texas
$1.87M -$557K -16,914 -22%
PVI
11
Pura Vida Investments
New York
$1.53M +$1.63M +49,678 New
ACP
12
Acuta Capital Partners
California
$1.5M -$1.4M -42,666 -47%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.44M +$83.6K +2,541 +6%
BlackRock
14
BlackRock
New York
$1.11M -$53.1K -1,614 -4%
Bank of Montreal
15
Bank of Montreal
Ontario, Canada
$962K -$48.9K -1,485 -5%
GCP
16
GSA Capital Partners
United Kingdom
$722K +$27.2K +828 +4%
Goldman Sachs
17
Goldman Sachs
New York
$660K -$440K -13,371 -38%
PHP
18
Parkman Healthcare Partners
Connecticut
$548K -$1.14M -34,667 -66%
RC
19
RBF Capital
California
$544K -$113K -3,439 -16%
RJA
20
Raymond James & Associates
Florida
$532K -$24.4K -743 -4%
AA
21
AlphaCentric Advisors
Puerto Rico
$469K -$301K -9,133 -38%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$440K -$201K -6,120 -30%
SM
23
Sabby Management
Florida
$435K +$464K +14,099 New
E
24
Ergoteles
New York
$432K -$14.4K -439 -3%
Northern Trust
25
Northern Trust
Illinois
$425K -$15.7K -476 -3%
1
2 3 4

GYRE Hedge Fund Activity: Q3 2021 in Review

65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2021, worth a combined $75.5M — down 14% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GYRE and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 9 added.

The largest buyer was OrbiMed, adding an estimated $2.6M. The largest seller was Stonepine Capital Management, cutting an estimated $1.94M.

  • 65 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $75.5M of Gyre Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
  • The largest Gyre Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $2.6M added.
  • The largest Gyre Therapeutics seller in Q3 2021 was Stonepine Capital Management, an estimated $1.94M sold.

Based on aggregated 13F filings for Q3 2021.